National
ENDA was focus of Log Cabin meeting with Romney
No commitments on specific legislation
Republican presidential nominee Mitt Romney (center) with Log Cabin’s R. Clarke Cooper (left) and former U.S. Rep. Jim Kolbe (photo courtesy Log Cabin)
A meeting that took place at a Virginia farmhouse between officials from Log Cabin Republicans and Republican presidential nominee Mitt Romney included a discussion about workplace non-discrimination, but attendees who spoke to the Washington Blade wouldn’t enumerate any commitments made by Romney.
R. Clarke Cooper, Log Cabin’s executive director, said workplace non-discrimination protections were the focus of the meeting, which took place Oct. 17 at Greenwood Farm in Leesburg, Va., which was a precursor the organization’s endorsement of the candidate announced on Tuesday.
The Log Cabin chief was non-commital when asked if he gathered from the meeting that Romney would sign a version of the Employment Non-Discrimination Act if it reached his desk.
“I can say with confidence that the Romney administration would work on desirable outcomes for workplace non-discrimination,” Cooper said. “I’m going to leave it broad like that because I think there’s room for administrative action as well as legislative. I also think it’s probably fair to say that legislation in a form of an ENDA or an ENDA-like legislation is certainly realistic.”
The Nation’s Ben Adler reported that Romney secretly promised Log Cabin he would sign ENDA, but doesn’t want to make that position public for fear of upsetting the religious right. Nowhere in the current version of The Nation’s piece does Cooper say he received a commitment on ENDA. In conversations with the Blade, Cooper insisted Romney never committed to signing any legislation.
Previously, the Washington Blade reported Log Cabin was seeking clarity on ENDA before making its endorsement decision. Romney supported the legislation as a U.S. Senate candidate in 1994, but in later years backed away from that support. The GOP nominee hasn’t addressed the legislation over the course of the 2012 presidential campaign.
During the meeting, Cooper said Romney was “very interested” in talking about different state laws on workplace discrimination for LGBT people. A total of 21 states have laws barring job discrimination against gay, lesbian and bisexual people; 16 states and D.C. protect all LGBT people from job bias.
“He is aware that there is a kind of patchwork or quilt of states that don’t, and that inequity was something of discussion,” Cooper said. “Some states have it, and some states don’t and this is where it gets confusing and problematic from an administrative standpoint as well.”
Cooper said he impressed upon Romney that ENDA would be consistent with his goals for economic stimulus and job growth because many major businesses have non-discrimination policies in place and discrimination may be preventing LGBT Americans from entering the workforce.
Asked if there was any portion of the current version of the legislation to which Romney objected, Cooper said Romney didn’t express concern about any particular language and did not object to protecting people from discrimination on the basis of gender identity.
According to Cooper, the Romney campaign took the lead in initiating the meeting — not Log Cabin — after a series of discussions between the group and the campaign. Those in attendance at the meeting, which lasted about 15 minutes, were Romney, gay former U.S. House Rep. Jim Kolbe and Log Cabin staffer Casey Pick and a Romney staffer. Neither Cooper nor Kolbe would identify the campaign staffer who accompanied Romney.
Kolbe, a Log Cabin member who’s also a trustee of the organization, stopped short of saying Romney offered any firm commitments on federal workplace non-discrimination protections, but said they were discussed during the meeting.
“He gave us a firm personal view of opposing workplace discrimination without endorsing ENDA specifically,” Kolbe said. “I think that it’s an area of opportunity where we have an opportunity to make a lot of headway with him.”
Kolbe said he also brought up immigration issues affecting same-sex couples — such as the inability of gay Americans to sponsor their foreign partners for residency. Kolbe faces that problem with his own partner, Hector Alfonso. Kolbe said Romney acknowledged him by nodding, but offered no further response.
According to Cooper, the meeting was a culmination of discussions that took place between between Log Cabin and the Romney campaign on issues of concern to the organization — including LGBT issues — over the course of the year.
Cooper said he’s previously spoken to Romney — notably during an exchange following the candidate’s speech at the Conservative Political Action Committee where the Log Cabin chief said he disagreed with him on the Defense of Marriage Act — but the exchange at the farmhouse was their most extensive meeting.
“That was the most substantive meeting that we had with them,” Cooper said. “That was the culmination from dialogue meetings and information exchanges with various personnel on the campaign.”
One option that the White House has said President Obama would not take at this time is an executive order prohibiting federal contractors from discriminating against LGBT workers. Both Cooper and Kolbe said that directive wasn’t discussed at the meeting, but Log Cabin has engaged with the Romney campaign previously on the issue.
Asked if the Romney campaign has offered any commitment on the executive order, Cooper replied that it would be in line with the candidate’s position that he opposes discrimination.
“I don’t want to get ahead of the governor on this, but I can tell you that was something on the table,” Cooper said.
While shying away from making any firm commitments on workplace protections, Cooper said Romney was firm deciding not to overturn “Don’t Ask, Don’t Tell” repeal or hospital visitation rights for same-sex couples, which the Obama administration already mandated for hospitals receiving Medicare and Medicaid funds.
Both positions were articulated by Romney before, but Romney’s commitment to the latter came into question over the weekend when Romney adviser Bay Buchanan told Buzzfeed on Saturday Romney still supports a Federal Marriage Amendment, but believes hospital visitation should be determined by the states under the Tenth Amendment.
“There’s not going to be a retreat by President Romney on repeal of ‘Don’t Ask, Don’t Tell,” Cooper said. “There’s not going to be a retreat on hospital visitation.”
Cooper said he didn’t get a sense from Romney on how high a priority passing a Federal Marriage Amendment would be for the candidate, but said he impressed upon Romney the organization’s desire to repeal the Defense of Marriage Act.
“We were very, very clear not only to Gov. Romney, but to the campaign staff that were working to repeal the Defense of Marriage Act,” Cooper said. “That was part of our legislative portfolio. They clearly understood that.”
The Romney campaign didn’t immediately respond to the Washington Blade’s request for comment on the meeting.
Federal Government
Holiday week brings setbacks for Trump-Vance trans agenda
Federal courts begin to deliver end-of-year responses to lawsuits involving federal transgender healthcare policy.
While many Americans took the week of Christmas to rest and relax, LGBTQ politics in the U.S. continued to shift. This week’s short recap of federal updates highlights two major blows to the Trump-Vance administration’s efforts to restrict gender-affirming care for minors.
19 states sue RFK Jr. to end gender-affirming care ban
New York Attorney General Letitia James announced on Tuesday that the NYAG’s office, along with 18 other states (and the District of Columbia), filed a lawsuit to stop U.S. Health and Human Services (HHS) Secretary Robert F. Kennedy Jr. from restricting gender-affirming care for minors.
In the press release, Attorney General James stressed that the push by the Trump-Vance administration’s crusade against the transgender community — specifically transgender youth — is a “clear overreach by the federal government” and relies on conservative and medically unvalidated practices to “punish providers who adhere to well-established, evidence-based care” that support gender-affirming care.
“At the core of this so-called declaration are real people: young people who need care, parents trying to support their children, and doctors who are simply following the best medical evidence available,” said Attorney General James. “Secretary Kennedy cannot unilaterally change medical standards by posting a document online, and no one should lose access to medically necessary health care because their federal government tried to interfere in decisions that belong in doctors’ offices. My office will always stand up for New Yorkers’ health, dignity, and right to make medical decisions free from intimidation.”
The lawsuit is a direct response to HHS’ Dec. 18 announcement that it will pursue regulatory changes that would make gender-affirming health care for transgender children more difficult, if not impossible, to access. It would also restrict federal funding for any hospital that does not comply with the directive. KFF, an independent source for health policy research, polling, and journalism, found that in 2023 federal funding covered nearly 45% of total spending on hospital care in the U.S.
The HHS directive stems directly from President Donald Trump’s Jan. 28 Executive Order, Protecting Children From Chemical and Surgical Mutilation, which formally establishes U.S. opposition to gender-affirming care and pledges to end federal funding for such treatments.
The American Medical Association, the nation’s largest and most influential physician organization, has repeatedly opposed measures like the one pushed by President Trump’s administration that restrict access to trans health care.
“The AMA supports public and private health insurance coverage for treatment of gender dysphoria and opposes the denial of health insurance based on sexual orientation or gender identity,” a statement on the AMA’s website reads. “Improving access to gender-affirming care is an important means of improving health outcomes for the transgender population.”
The lawsuit also names Oregon, Washington, California, Colorado, Connecticut, Delaware, the District of Columbia, Illinois, Maine, Maryland, Massachusetts, Michigan, Minnesota, New Mexico, Pennsylvania, Rhode Island, Vermont, and Wisconsin as having joined New York in the push against restricting gender-affirming care.
At the HHS news conference last Thursday, Jim O’Neill, deputy secretary of the department, asserted, “Men are men. Men can never become women. Women are women. Women can never become men.”
DOJ stopped from gaining health care records of trans youth
U.S. District Judge Cathy Bissoon blocked an attempt by the Department of Justice (DOJ) to gain “personally identifiable information about those minor transgender patients” from the University of Pittsburgh Medical Center (UPMC), saying the DOJ’s efforts “fly in the face of the Supreme Court.”
Journalist Chris Geidner originally reported the news on Dec. 25, highlighting that the Western District of Pennsylvania judge’s decision is a major blow to the Trump-Vance administration’s agenda to curtail transgender rights.
“[T]his Court joins the others in finding that the government’s demand for deeply private and personal patient information carries more than a whiff of ill intent,” Bissoon wrote in her ruling. “This is apparent from its rhetoric.”
Bissoon cited the DOJ’s “incendiary characterization” of trans youth care on the DOJ website as proof, which calls the practice politically motivated rather than medically sound and seeks to “…mutilate children in the service of a warped ideology.” This is despite the fact that a majority of gender-affirming care has nothing to do with surgery.
In United States v. Skrmetti, the Supreme Court ruled along party lines that states — namely Tennessee — have the right to pass legislation that can prohibit certain medical treatments for transgender minors, saying the law is not subject to heightened scrutiny under the Equal Protection Clause of the Fourteenth Amendment because it does not involve suspect categories like race, national origin, alienage, and religion, which would require the government to show the law serves a compelling interest and is narrowly tailored, sending decision-making power back to the states.
“The government cannot pick and choose the aspects of Skrmetti to honor, and which to ignore,” Judge Bissoon added.
The government argued unsuccessfully that the parents of the children whose records would have been made available to the DOJ “lacked standing” because the subpoena was directed at UPMC and that they did not respond in a timely manner. Bissoon rejected the timeliness argument in particular as “disingenuous.”
Bissoon, who was nominated to the bench by then-President Obama, is at least the fourth judge to reject the DOJ’s attempted intrusion into the health care of trans youth according to Geidner.
A Wider Bridge on Friday announced it will shut down at the end of the month.
The group that “mobilizes the LGBTQ community to fight antisemitism and support Israel and its LGBTQ community” in a letter to supporters said financial challenges prompted the decision.
“After 15 years of building bridges between LGBTQ communities in North America and Israel, A Wider Bridge has made the difficult decision to wind down operations as of Dec. 31, 2025,” it reads.
“This decision comes after challenging financial realities despite our best efforts to secure sustainable funding. We deeply appreciate our supporters and partners who made this work possible.”
Arthur Slepian founded A Wider Bridge in 2010.
The organization in 2016 organized a reception at the National LGBTQ Task Force’s Creating Change Conference in Chicago that was to have featured to Israeli activists. More than 200 people who protested against A Wider Bridge forced the event’s cancellation.
A Wider Bridge in 2024 urged the Capital Pride Alliance and other Pride organizers to ensure Jewish people can safely participate in their events in response to an increase in antisemitic attacks after Hamas militants attacked Israel on Oct. 7, 2023.
The Jewish Telegraphic Agency reported authorities in Vermont late last year charged Ethan Felson, who was A Wider Bridge’s then-executive director, with lewd and lascivious conduct after alleged sexual misconduct against a museum employee. Rabbi Denise Eger succeeded Felson as A Wider Bridge’s interim executive director.
A Wider Bridge in June honored U.S. Rep. Debbie Wasserman Schultz (D-Fla.) at its Pride event that took place at the Capital Jewish Museum in D.C. The event took place 15 days after a gunman killed two Israeli Embassy employees — Yaron Lischinsky and Sarah Milgrim — as they were leaving an event at the museum.
“Though we are winding down, this is not a time to back down. We recognize the deep importance of our mission and work amid attacks on Jewish people and LGBTQ people – and LGBTQ Jews at the intersection,” said A Wider Bridge in its letter. “Our board members remain committed to showing up in their individual capacities to represent queer Jews across diverse spaces — and we know our partners and supporters will continue to do the same.”
Editor’s note: Washington Blade International News Editor Michael K. Lavers traveled to Israel and Palestine with A Wider Bridge in 2016.
The White House
‘Trump Rx’ plan includes sharp cuts to HIV drug prices
President made announcement on Friday
President Donald Trump met with leaders from some of the world’s largest pharmaceutical companies at the White House on Friday to announce his new “Trump Rx” plan and outline efforts to reduce medication costs for Americans.
During the roughly 47-minute meeting in the Roosevelt Room, Trump detailed his administration’s efforts to cut prescription drug prices and make medications more affordable for U.S. patients.
“Starting next year, American drug prices will come down fast, furious, and will soon be among the lowest in the developed world,” Trump said during the meeting. “For decades, Americans have been forced to pay the highest prices in the world for prescription drugs by far … We will get the lowest price of anyone in the world.”
Trump signed an executive order in May directing his administration “to do everything in its power to slash prescription drug prices for Americans while getting other countries to pay more.”
“This represents the greatest victory for patient affordability in the history of American health care, by far, and every single American will benefit,” he added.
Several pharmaceutical executives stood behind the president during the announcement, including Sanofi CEO Paul Hudson, Novartis CEO Vas Narasimhan, Genentech CEO Ashley Magargee, Boehringer Ingelheim (USA) CEO Jean-Michel Boers, Gilead Sciences CEO Dan O’Day, Bristol Myers Squibb General Counsel Cari Gallman, GSK CEO Emma Walmsley, Merck CEO Robert Davis, and Amgen Executive Vice President Peter Griffith.
Also in attendance were Health and Human Services Secretary Robert F. Kennedy Jr., Commerce Secretary Howard Lutnick, Centers for Medicare and Medicaid Services Administrator Mehmet Oz, and Food and Drug Administration Commissioner Marty Makary.
Under the Trump Rx plan, the administration outlined a series of proposed drug price changes across multiple companies and therapeutic areas. Among them were reductions for Amgen’s cholesterol-lowering drug repatha from $573 to $239; Bristol Myers Squibb’s HIV medication reyataz from $1,449 to $217; Boehringer Ingelheim’s type 2 diabetes medication jentadueto from $525 to $55; Genentech’s flu medication xofluza from $168 to $50; and Gilead Sciences’ hepatitis C medication epclusa from $24,920 to $2,425.
Additional reductions included several GSK inhalers — such as the asthma inhaler advair diskus 500/50, from $265 to $89 — Merck’s diabetes medication januvia from $330 to $100, Novartis’ multiple sclerosis medication mayzent from $9,987 to $1,137, and Sanofi’s blood thinner plavix from $756 to $16. Sanofi insulin products would also be capped at $35 per month’s supply.
These prices, however, would only be available to patients who purchase medications directly through TrumpRx. According to the program’s website, TrumpRx “connects patients directly with the best prices, increasing transparency, and cutting out costly third-party markups.”
Kennedy spoke after Trump, thanking the president for efforts to lower pharmaceutical costs in the U.S., where evidence has shown that drug prices — including both brand-name and generic medications — are nearly 2.78 times higher than prices in comparable countries. According to the Pharmaceutical Research and Manufacturers of America, roughly half of every dollar spent on brand-name drugs goes to entities that play no role in their research, development, or manufacturing.
“This is affordability in action,” Kennedy said. “We are reversing that trend and making sure that Americans can afford to get the life-saving solutions.”
Gilead CEO Dan O’Day also spoke about how the restructuring of drug costs under TrumpRx, combined with emerging technologies, could help reduce HIV transmission — a virus that, if untreated, can progress to AIDS. The LGBTQ community remains disproportionately affected by HIV.
“Thank you, Mr. President — you and the administration,” O’Day said. “I think this objective of achieving the commitment to affordability and future innovation is extraordinary … We just recently launched a new medicine that’s only given twice a year to prevent HIV, and we’re working with Secretary Kennedy and his entire team, as well as the State Department, as a part of your strategy to support ending the epidemic during your term.
“I’ve never been more optimistic about the innovation that exists across these companies and the impact this could have on America’s health and economy,” he added.
Trump interjected, asking, “And that’s working well with HIV?”
“Yes,” O’Day replied.
“It’s a big event,” Trump said.
“It literally prevents HIV almost 100 percent given twice a year,” O’Day responded.
A similar anti-HIV medication is currently prescribed more than injectable form mentioned by O’Day. PrEP, is a medication regimen proven to significantly reduce HIV infection rates for people at high risk. Without insurance, brand-name Truvada can cost roughly $2,000 per month, while a generic version costs about $60 per month.
Even when medication prices are reduced, PrEP access carries additional costs, including clinic and laboratory fees, office visits, required HIV and sexually transmitted infection testing, adherence services and counseling, and outreach to potentially eligible patients and providers.
According to a 2022 study, the annual total cost per person for PrEP — including medication and required clinical and laboratory monitoring — is approximately $12,000 to $13,000 per year.
The TrumpRx federal platform website is now live at TrumpRx.gov, but the program is not slated to begin offering reduced drug prices until January.
Looking back at the 10 biggest A&E stories of 2025
Kazakh president signs anti-LGBTQ propaganda bill
Top 10 LGBTQ local news stories of 2025
The 25 greatest queer movies of the 21st century so far
How to cope when a partner gives you the silent treatment
Your guide to D.C.’s queer New Year’s Eve parties
Holiday week brings setbacks for Trump-Vance trans agenda
Out actor talks lead role in ‘Fiddler on the Roof’
This gay author sees dead people
